SPOTLIGHT: Santhera inks licensing deal


Sweden's Biovitrum has acquired the rights to Santhera's DPP-IV inhibitor program to select and develop compounds and sell future drugs for a range of metabolic diseases, including type 2 diabetes, obesity and metabolic syndrome. Santhera gains €4 million up front with more than €50 million in back end potential. Story